FALSE0001818093Nasdaq00018180932025-02-252025-02-250001818093us-gaap:CommonStockMember2025-02-252025-02-25

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 25, 2025
 
The Beauty Health Company
(Exact name of registrant as specified in its charter)  
 
Delaware 001-39565 85-1908962
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
2165 Spring Street
Long Beach, CA
(Address of principal executive offices)

90806
(Zip Code)
(800) 603-4996
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Class A Common Stock, par value $0.0001 per share SKIN 
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐  
 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Designation of Ronald Menezes as an Executive Officer and Section 16 Officer

On February 25, 2025, the Board of Directors (the "Board") of The Beauty Health Company (the "Company") determined that based on the evolution of Mr. Ronald Menezes’ role as Chief Revenue Officer of the Company, the scope of his duties has increased to include policy making functions. Due to this determination, the Board designated Mr. Menezes as an executive officer, as that term is defined in 17 C.F.R. § 240.3b-7 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), thus making Mr. Menezes an executive officer subject to Section 16 of the Exchange Act (a "Section 16 Officer").

As previously disclosed in the press release attached to this Current Report on Form 8-K (this "Current Report") as Exhibit 99.1, on October 15, 2024, the Company appointed Mr. Menezes, age 62, to serve as Chief Revenue Officer of the Company, effective October 15, 2024 (the "Menezes Effective Date").

Prior to his role as Chief Revenue Officer, Mr. Menezes served as a director, President and Chief Executive Officer of Sientra, Inc., a publicly traded medical aesthetic products company that was formerly listed on NASDAQ, from November 2020 through June 2024. Prior to joining Sientra, Inc., Mr. Menezes served as President and General Manager for Almirall U.S. – Dermatology from August 2017 until November 2020. Prior to joining Almirall, Mr. Menezes served as Vice President of Sales and Operations of Assertio Therapeutics, Inc. (formerly Depomed Inc.), a specialty pharmaceutical company, from 2016 until August 2017. Formerly, Mr. Menezes served in a series of leadership roles at Allergan plc, Abbott Laboratories, Astellas Pharma Inc., Pfizer Inc. and Eli, Lilly and Co. Mr. Menezes also serves as a director of Diverse Biotech, Inc., a company specializing in oncology drug discovery. Mr. Menezes holds a B.S. in International Business from Brigham Young University.

There are no arrangements or understandings between Mr. Menezes and any other person pursuant to which Mr. Menezes was appointed to serve as the Chief Revenue Officer of the Company on a permanent basis. There are no family relationships between Mr. Menezes and any of the Company’s directors or executive officers. Mr. Menezes has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

Menezes Offer Letter

In connection with his role as Chief Revenue Officer, the Company entered into an offer letter with Mr. Menezes, which became effective as of the Menezes Effective Date (the "Menezes Offer Letter"), pursuant to which Mr. Menezes receives (i) an annual base salary of $450,000, (ii) a one-time cash bonus of $100,000 (subject to repayment in full in the event of his voluntary resignation within one year following the Menezes Effective Date other than for good reason), (iii) an annual discretionary cash bonus (commencing with fiscal year 2025) with a target equal to 60% of Mr. Menezes’ annual base salary (the "Annual Bonus"), and (iv) a one-time long-term incentive new hire equity award to be issued in the form of restricted stock units ("RSUs") with a grant-date value of $800,000, which RSUs will vest ratably on an annual basis over a three-year period from the date of grant, subject to his continued service. Mr. Menezes will also be eligible for one or more future grants of long-term incentive awards under the Company’s 2021 Incentive Award Plan, as amended (the "Plan"), to be determined by the compensation committee of the Board (the "Compensation Committee"). Mr. Menezes will also be eligible to participate in and be covered by all employee benefit programs maintained by the Company on the same terms as are generally applicable to other senior executives of the Company, subject to his meeting applicable eligibility requirements. Mr. Menezes’ base salary and target Annual Bonus will be subject to periodic review and adjustment from time to time in the discretion of the Board or the Compensation Committee.

The foregoing description of the Menezes Offer Letter is not complete and is subject to and qualified in its entirety by reference to the text of the Menezes Offer Letter, which is filed as Exhibit 10.1 to this Current Report and incorporated herein by reference.

Designation of Sheri Lewis as an Executive Officer and Section 16 Officer

On February 25, 2025, the Board determined that based on the evolution of Ms. Sheri Lewis’ role as Chief Supply Chain and Operations Officer of the Company, the scope of her duties has increased to include policy making functions. Due to this determination, the Board designated Ms. Lewis as an executive officer, as that term is defined in 17 C.F.R. § 240.3b-7 of the Exchange Act, thus making Ms. Lewis an executive officer subject to Section 16 of the Exchange Act.



As previously disclosed on the press release attached to this Current Report as Exhibit 99.2, on April 9, 2024, Ms. Lewis, age 59, was appointed to serve as Chief Supply Chain and Operations Officer, effective April 9, 2024 (the "Lewis Effective Date").

Prior to her role as Chief Supply Chain and Operations Officer, Ms. Lewis established herself as an industry leader in the areas of global supply chain and manufacturing operations. From January 2021 to April 2024, Ms. Lewis was the EVP of global supply chain operations at Avantor, Inc., where she served on the executive committee and led Avantor's global integrated supply chain strategy and operational performance with oversight of over 3,500 associates. From September 2009 to December 2020, Ms. Lewis served in various positions at Medtronic, most recently as VP of global operations, responsible for 32 global manufacturing sites, 19,000 people, and the end-to-end value stream. Earlier, Ms. Lewis held positions of increasing responsibility at Honeywell, including VP of materials management, planning and procurement, and at Fabrico, where she was general manager. Ms. Lewis holds a Bachelor of Arts degree in organization management from Concordia University, and is the recipient of a number of awards, including Global Operations and Business Services Leader of the Year.

There are no arrangements or understandings between Ms. Lewis and any other person pursuant to which Ms. Lewis was appointed to serve as the Chief Supply Chain and Operations Officer of the Company on a permanent basis. There are no family relationships between Ms. Lewis and any of the Company’s directors or executive officers. Ms. Lewis has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

Lewis Offer Letter

In connection with her role as Chief Supply Chain and Operations Officer, the Company entered into an offer letter with Ms. Lewis, which became effective as of the Lewis Effective Date (the "Lewis Offer Letter"), pursuant to which Ms. Lewis receives (i) an annual base salary of $485,000, (ii) a one-time cash bonus of $75,000 (subject to repayment in full in the event of her voluntary resignation within one year following the Lewis Effective Date other than for good reason), (iii) an annual discretionary cash bonus (commencing with fiscal year 2024 on a pro rata basis) with a target equal to 60% of Ms. Lewis’ annual base salary (the "Lewis Annual Bonus"), (iv) a one-time long-term incentive new hire equity award to be issued in the form of RSUs with a grant-date value of $1,181,250, which RSUs will vest ratably on an annual basis over a three-year period from the date of grant subject to her continued service, and (v) a one-time long-term incentive new hire grant of equity in the form of performance-based restricted stock units ("PSUs") with a grant-date value of $393,750. Ms. Lewis will also be eligible for one or more future grants of long-term incentive awards under the Plan, to be determined by the Board or the Compensation Committee. Ms. Lewis will also be eligible to participate in and be covered by all employee benefit programs maintained by the Company on the same terms as are generally applicable to other senior executives of the Company, subject to her meeting applicable eligibility requirements. Ms. Lewis’ base salary and Lewis Annual Bonus will be subject to periodic review and adjustment from time to time in the discretion of the Board or the Compensation Committee.

The foregoing description of the Lewis Offer Letter is not complete and is subject to and qualified in its entirety by reference to the text of the Lewis Offer Letter, which is filed as Exhibit 10.2 to this Current Report and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On October 15, 2024, the Company issued a press release announcing the appointment of Mr. Menezes as the Company’s new Chief Revenue Officer, a copy of which is attached to this Current Report as Exhibit 99.1 and is incorporated herein by reference.

On April 9, 2024, the Company issued a press release announcing the appointment of Ms. Lewis as the Company’s new Chief Supply Chain and Operations Officer, a copy of which is attached to this Current Report as Exhibit 99.2 and is incorporated herein by reference.

The information set forth under Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.





Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


† Confidential portions of this exhibit were redacted pursuant to Item 601(b)(10) of Regulation S-K, and the Company agrees to furnish to the SEC a copy of any omitted schedule and/or exhibit upon request.




















SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: February 28, 2025The Beauty Health Company
By:/s/ Michael Monahan
Name:Michael Monahan
Title:Chief Financial Officer


CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED
October 9, 2024 Ron Menezes
[*****]

Dear Ron,
We are excited to extend you an offer to join Hydrafacial LLC, a BeautyHealth Company, as our Chief Revenue Officer. In this role, you will report directly to Marla Beck, Chief Executive Officer, and your position will be based out of your residence in the [*****] area with frequent travel in the field as needed. Your start date will be October 14, 2024. This offer is contingent upon satisfactory completion of your background check and references.
This is an exempt position, and your annual base compensation will be $450,000.00, paid biweekly in accordance with the Company’s standard payroll practices and subject to all regular withholdings.
You will be eligible to participate in and earn a cash performance bonus under the Corporate Annual Incentive Plan where your annualized at-target bonus will be 60% of the base salary earnings for this role. The actual amount of the annual bonus will be determined based on achievement of specified levels of performance goals set by the Company’s Board of Directors. The bonus plan may be amended or changed from time to time. Any annual bonus that becomes payable will be paid at such time as annual bonuses are generally paid to senior executives, subject to your continued employment with the Company through the applicable payment date. The annual bonus plan year runs from January through December and you will be eligible for this bonus beginning in 2025 (paid in March 2026).
We are pleased to offer you a signing bonus of $100,000.00 payable in two installments. This first installment of $50,000.00 will be paid in the first 30-days after your start date. The second installment of $50,000.00 will be paid 6-months after your start date. This signing bonus is taxable, and all regular payroll taxes will be withheld. In the event you voluntarily resign from BeautyHealth within 12-months of your date of hire for reason other than Good Reason, you will be responsible for reimbursing the company for the entire gross signing bonus.
You will be granted a Long-Term Incentive grant of $800,000.00 Restricted Stock Units (RSUs) under the Beauty Health Company 2021 Incentive Award Plan. The grant and vesting schedule will be subject to approval of the Board of Directors of the BeautyHealth company, the terms and conditions of the Beauty Health Company’s 2021 Incentive Award Plan, and the grant agreement to be entered into between Employee and the Company. These RSU’s will vest ratably over three years from the date of the grant, which will be the first of the month following your date of hire, subject to continued service.

You will be eligible to receive one or more grants of long-term incentive awards (“Awards”) for each fiscal year of employment with the Company based on performance, affordability, market data, and the Company’s go-forward performance / stock price. The amount (if any), type and terms and conditions (including vesting conditions) of any such Award will be determined by the Compensation Committee in its sole discretion. Each Award will be subject to the terms and conditions of The Beauty Health Company 2021 Incentive Award Plan, subject to and contingent upon the approval of the Incentive Plan by the Board and the stockholders of the Company, or any successor plan, and an award agreement entered into between the Company and you.


Ron Menezes Offer Letter Page 2 – October 9, 2024

You will be eligible for all company benefits, subject to the terms and conditions of each program. This includes the permissive PTO plan, all health and welfare plans, as well as the 401k retirement savings plan. These plans are outlined in the 2024 Employee Benefits Summary (attached).
On or before your first day of employment, you will receive a link to the new hire packet. It contains all the paperwork you will need to complete and submit. On your first day, please be sure to bring identification documents that verify your identity and employment eligibility. This is required by the Department of Homeland Security. Should we not receive the required documentation within three (3) days from your start date, we will have to withdraw our offer of employment. If you have any questions as to which documents are required, please refer to the enclosed Form I-9 list of acceptable documents.
As an employee of the Company, you will be subject to the Company’s policies and procedures as they may be amended from time to time. Either you or the Company may end the employment relationship at any time, with or without cause or advance notice. We are an at-will employer; therefore, this letter does not constitute an employment contract.
Ron, we are excited to invite you to join the team at BeautyHealth! Our team members are talented, highly motivated professionals with a tremendous passion for our products and services.
We look forward to receiving your acceptance by October 10, 2024. Please contact me at [*****] should you have any questions about this offer.
Sincerely,
/s/ Celeste Ortiz
Celeste Ortiz
Chief Human Resources Officer The BeautyHealth Company


Accepted and agreed to on (Date): October 9, 2024

Employee Signature:     /s/ Ron Menezes
            Ron Menezes


CERTAIN INFORMATION, IDENTIFIED BY [*****], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL, AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED


March 25, 2024
Sheri Lewis
[*****]

Dear Sheri,
We are excited to extend you an offer to join Hydrafacial LLC, a BeautyHealth Company, as our Chief Supply Chain and Operations Officer. In this role, you will report directly to Marla Beck, President and Chief Executive Officer, and your position will be based out of your residence in [*****] with frequent travel to our Burnett Distribution Center based in Long Beach, CA. Your start date will be April 8, 2024.
This offer is contingent upon satisfactory completion of your background check.
This is an exempt position, and your annual base compensation will be $485,000.00, paid biweekly in accordance with the Company’s standard payroll practices and subject to all regular withholdings.
You will be eligible to participate in and earn a cash performance bonus under the Corporate Annual Incentive Plan where your annualized at-target bonus will be 60% of the base salary earnings for this role. The actual amount of the annual bonus will be determined based on achievement of specified levels of performance goals set by the Company’s Board of Directors. The bonus plan may be amended or changed from time to time. Any annual bonus that becomes payable will be paid at such time as annual bonuses are generally paid to senior executives, subject to your continued employment with the Company through the applicable payment date. The annual bonus plan year runs from January through December and any 2024 annual bonus earned will be pro-rated based on your hire date.
We are also pleased to offer you a signing bonus of $75,000. This bonus will be paid in one lump sum in a separate check within 30 days after you start employment with Hydrafacial LLC, a BeautyHealth Company. This signing bonus is taxable, and all regular payroll taxes will be withheld. In the event you voluntarily resign from the Company within 12 months of your date of hire for reason other than a Good Reason (as defined in the Severance Plan), you will be responsible for reimbursing the company for the entire gross signing bonus.
Under the Company’s 2021 Incentive Award Plan, you will be granted a Long-Term Incentive new hire grant of $1,181,250.00 in form of restricted stock units (“RSUs”). The RSU will vest ratably over 3 years from the date of grant subject to your continued service. The grant will be subject to the terms and conditions of the 2021 BeautyHealth Company Incentive Plan and grant agreement, to be entered into between you and the Company.
You will be granted a Long-Term Incentive grant of $393,750.00 Performance-Based Restricted Stock Units (PSUs) under the Beauty Health Company 2021 Incentive Award Plan. The grant and vesting schedule will be subject to the terms and conditions of the Beauty Health Company’s 2021 Incentive Award Plan and grant agreement to be entered into between Employee and the Company.


Sheri Lewis Offer Letter March 25, 2024, Page 2

You will be eligible to receive one or more grants of long-term incentive awards (“Awards”) for each fiscal year of employment with the Company based on performance, affordability, market data, and the Company’s go-forward performance / stock price. The amount (if any), type and terms and conditions (including vesting conditions) of any such Award will be determined by the Compensation Committee in its sole discretion. Each Award will be subject to the terms and conditions of The Beauty Health Company 2021 Incentive Award Plan, subject to and contingent upon the approval of the Incentive Plan by the Board and the stockholders of the Company, or any successor plan, and an award agreement entered into between the Company and you.
You will be eligible for all company benefits, subject to the terms and conditions of each program. This includes the permissive PTO plan, all health and welfare plans as well as the 401k retirement savings plan. These plans are outlined in the 2024 Employee Benefits Summary (attached).
On or before your first day of employment, you will receive a link to the new hire packet. It contains all the paperwork you will need to complete and submit. On your first day, please be sure to bring identification documents that verify your identity and employment eligibility. This is required by the Department of Homeland Security. Should we not receive the required documentation within three (3) days from your start date, we will have to withdraw our offer of employment. If you have any questions as to which documents are required, please refer to the enclosed Form I-9 list of acceptable documents.
As an employee of the Company, you will be subject to the Company’s policies and procedures as they may be amended from time to time. Either you or the Company may end the employment relationship at any time, with or without cause or advance notice. We are an at-will employer; therefore, this letter does not constitute an employment contract.
Sheri, we are excited to invite you to join the team at Beauty Health! Our team members are talented, highly motivated professionals with a tremendous passion for our products and services.
We look forward to receiving your acceptance by Wednesday, March 27, 2024. Please contact me at [*****] should you have any questions about this offer.
Sincerely,
/s/ Celeste Ortiz
Celeste Ortiz
Chief Human Resources Officer The BeautyHealth Company

Accepted and agreed to on (Date): March 27, 2024

Employee Signature:     /s/ Sheri Lewis
            Sheri Lewis


image_01.jpg


The Beauty Health Company Strengthens Commercial Leadership Team with
Chief Revenue Officer and Chief Marketing Officer Appointments

LONG BEACH, Calif., October 15, 2024 - The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced the appointment of two accomplished industry executives to its commercial leadership team. Ron Menezes will join Beauty Health as Chief Revenue Officer and Carrie Caulkins will join the Company as Chief Marketing Officer, effective October 15, 2024, with both reporting to the Company’s Chief Executive Officer, Marla Beck. Mr. Menezes assumes his new role from Dan (“Doc”) Watson, who is leaving Beauty Health and will assist with the transition through year-end. Ms. Caulkins fills an open position.

Marla Beck commented on the appointments, “We are thrilled to welcome Ron and Carrie to the executive team as we continue to drive the transformation of Beauty Health to elevate experiences and results for our clients. Both are accomplished, performance-driven leaders that have achieved outstanding results through their execution of successful go-to-market strategies in the medical aesthetics industry. The Board of Directors and I are confident that their expertise further strengthens our senior leadership team and will enable us to achieve our near-term priorities, positioning Beauty Health for consistent sales and profit growth to unlock Hydrafacial’s growth potential. I want to thank Doc for his dedication and hard work and wish him all the best in his future endeavors.”

Ron Menezes is a seasoned executive with over 20 years of leadership experience in product commercialization and revenue generation at premier aesthetics, dermatology, and medical device companies, as well as high-growth startups. As former President and CEO of Sientra, he successfully revamped the company’s go-to-market strategy, significantly enhancing its market presence and driving substantial revenue growth and profitability. Previously, Mr. Menezes held sales leadership roles at Almirall Dermatology, Allergan, and Abbott, where he managed the sales organization for multi-million-dollar business units.

At BeautyHealth, Mr. Menezes will lead the global sales, business development, and customer training teams. He will also work closely with the executive management team to help shape and implement the company’s global go-to-market strategy and product innovation initiatives aimed at accelerating revenue growth and enhancing profitability.

Carrie Caulkins joins Beauty Health after eight years at Galderma, where she held several leadership positions overseeing the company's aesthetic pharmaceutical and medical device brands. As Vice President and Global Franchise Lead, she drove global business strategy, pipeline development, and product lifecycle management. Additionally, she served as Vice President of Marketing, where she focused on expanding the U.S. aesthetics market. Before her tenure at Galderma, Ms. Caulkins spent over a decade at Allergan, where she held various marketing and clinical leadership roles.

In her new role, Ms. Caulkins will lead Beauty Health’s global marketing initiatives to increase awareness, relevance, and affinity for the Hydrafacial brand. She will oversee the marketing and client experience teams, while collaborating with executive leadership to shape business strategy and product development with the goal of strengthening and expanding the Company’s market position.


image_01.jpg


About The Beauty Health Company
The Beauty Health Company (NASDAQ: SKIN) is a global category-creating company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies, and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in microneedling, and Keravive™ in scalp health. Together, with our powerful global community of estheticians, partners, and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at https://hydrafacial.com/find-a-provider/ and learn more at beautyhealth.com or LinkedIn. 

Investors: IR@beautyhealth.com
Press: press@beautyhealth.com





image_0.jpg

BEAUTYHEALTH NAMES SHERI LEWIS AS CHIEF SUPPLY CHAIN AND OPERATIONS OFFICER

LONG BEACH, Calif., April 9, 2024 – The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced that it has appointed Sheri Lewis as Chief Supply Chain and Operations Officer, effective immediately. Ms. Lewis will report to BeautyHealth’s President and Chief Executive Officer, Marla Beck.

“Sheri is a talented and deeply experienced executive who brings decades of valuable global operations expertise to BeautyHealth as we chart the future of the Company,” said Marla Beck, BeautyHealth President and Chief Executive Officer. “The Board of Directors and I are confident that her deep industry experience across global supply chain and operations will play a critical role in advancing our strategic objectives with the goal of further enhancing shareholder value.”

Before joining BeautyHealth, Ms. Lewis established herself as an industry leader in the areas of global supply chain and manufacturing operations. Most recently, Ms. Lewis was the EVP of global supply chain operations at Avantor, Inc., where she served on the executive committee and led the company’s global integrated supply chain strategy and operational performance with oversight of over 3,500 associates.

Prior, Ms. Lewis spent almost twelve years at Medtronic, most recently as VP of global operations, responsible for 32 global manufacturing sites, 19,000 people, and the end-to-end value stream. Earlier, Ms. Lewis held positions of increasing responsibility at Honeywell, including VP of materials management, planning and procurement, and at Fabrico, where she was general manager. Ms. Lewis holds a Bachelor of Arts degree in organization management from Concordia University, and is the recipient of a number of awards, including Global Operations and Business Services Leader of the Year.

“I’m thrilled to join The Beauty Health Company at such a pivotal moment in its history,” said Ms. Lewis. “BeautyHealth has become a leader in the space by developing world-class brands and products that have captured the loyalty of a global community of providers, partners, and consumers. I am confident in our ability to make marked progress in key operational areas to drive results across the entire value stream as we grow and evolve the business.”

Brad Hauser, current Chief Operations Officer, will be leaving BeautyHealth and will work closely with Sheri and other members of the executive team over the next few months to smoothly transition his responsibilities.

About The Beauty Health Company
The Beauty Health Company (NASDAQ: SKIN) is a global category-creating company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in microneedling, and Keravive™ in scalp health. Together, with our powerful global community of estheticians, partners and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at https://hydrafacial.com/find-a-provider, and learn more at beautyhealth.com or LinkedIn.



Investors: IR@beautyhealth.com
Press: press@beautyhealth.com

v3.25.0.1
Cover
Feb. 25, 2025
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Feb. 25, 2025
Entity Registrant Name The Beauty Health Company
Entity Incorporation, State or Country Code DE
Entity File Number 001-39565
Entity Tax Identification Number 85-1908962
Entity Address, Address Line One 2165 Spring Street
Entity Address, City or Town Long Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90806
City Area Code 800
Local Phone Number 603-4996
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001818093
Class A Common Stock, par value $0.0001 per share  
Entity Information [Line Items]  
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol SKIN
Security Exchange Name NASDAQ
Grafico Azioni Beauth Health (NASDAQ:SKIN)
Storico
Da Feb 2025 a Mar 2025 Clicca qui per i Grafici di Beauth Health
Grafico Azioni Beauth Health (NASDAQ:SKIN)
Storico
Da Mar 2024 a Mar 2025 Clicca qui per i Grafici di Beauth Health